Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

12 janv. 2025 10h00 HE | Source: Curevo Vaccine

Curevo Announces Positive Updated Phase 2 Data for Amezosvatein Shingles Vaccine

Updated Phase 2 data one year after the second vaccine dose, the anti-gE antibody immune response to amezosvatein continues to be non-inferior to Shingrix
09 janv. 2025 09h00 HE | Source: Lyell Immunopharma, Inc

Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

Accelerating IMPT-314 in large B-cell lymphoma; remain on track to initiate pivotal trial in the 3rd line+ setting in 2025 and expect to initiate a pivotal trial in the 2nd line by early...
08 janv. 2025 11h30 HE | Source: Curevo Vaccine

Curevo Vaccine to present at the 43rd Annual J.P. Morgan Healthcare Conference

Curevo Vaccine will present at the 2025 JPM Healthcare Conference on Wednesday January 15th.
06 janv. 2025 08h15 HE | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Ron Renaud, Kailera's President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025.
19 déc. 2024 08h00 HE | Source: Artios Pharma

Artios Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, United Kingdom and NEW YORK, December 19, 2024 – Artios Pharma Limited (“Artios”), a clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, today...